Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Next Previous
Search
Trial Profile

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiotensin II (Primary)
  • Indications Hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHOS-3
  • Sponsors La Jolla Pharmaceutical Company

    • Most Recent Events

    • 29 Aug 2019 According to a La Jolla Pharmaceutical Company media release, the ECs decision is applicable to the 28 European Union member countries. Approval will also be recognized in Iceland, Norway and Liechtenstein.
    • 29 Aug 2019 According to a La Jolla Pharmaceutical Company media release, based on data from this phase III study (ATHOS-3), the European Commission(EC) has approved GIAPREZA (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
    • 01 Aug 2019 According to a La Jolla Pharmaceutical Company media release, company expect a final approval decision on the GIAPREZA MAA by the EC in the third quarter of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top